유전자 편집 기술 시장 : 세계 및 지역별 분석 - 오퍼링별, 기술별, 용도별, 최종사용자별, 지역별 - 분석과 예측(2023-2032년)

Gene Editing Technologies Market - A Global and Regional Analysis: Focus on Offering, Technology, Application, End User, and Region - Analysis and Forecast, 2023-2032

US $ 2,750 ￦ 3,902,000

PDF and Excel (1-3 User License)

PDF 및 Excel 보고서를 동일 사업장에서 3명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 4,250 ￦ 6,031,000

PDF and Excel (Global License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계의 유전자 편집 기술 시장 규모는 2022년에 18억 1,000만 달러를 기록했습니다. 이 시장은 2023-2032년 27.50%의 CAGR로 확대하며, 2032년에는 163억 7,000만 달러에 달할 것으로 예측되고 있습니다.

세계의 유전자 편집 기술 시장에 대해 조사했으며, 시장의 개요와 오퍼링별, 기술별, 용도별, 최종사용자별, 지역별 동향 및 시장에 참여하는 기업의 개요 등을 제공하고 있습니다.

목차

제1장 제품의 정의

제2장 시장의 범위

제3장 조사 방법

제4장 시장 개요

제5장 업계의 전망

• 규제 상황
• 제품 벤치마킹
• 기술 도입 매트릭스
• 업계의 동향
• 특허 분석

제6장 세계의 유전자 편집 기술 시장 : 시장 역학

• 비즈니스 촉진요인
• 비즈니스 억제요인
• 비즈니스 기회

제7장 세계의 유전자 편집 기술 시장 : 경쟁 인사이트

• 주요 발전과 전략
• 주요 개발 분석
• 기업 점유율 분석

제8장 세계의 유전자 편집 기술 시장(오퍼링별), 금액(100만 달러), 2022-2032년

• 개요
• 유전자 편집 제품
• 유전자 편집 서비스

제9장 세계의 유전자 편집 기술 시장(기술별), 금액(100만 달러), 2022-2032년

• 개요
• CRISPR 유전자 편집 기술
• 비CRISPR 유전자 편집 기술

제10장 세계의 유전자 편집 기술 시장(용도별), 금액(100만 달러), 2022-2032년

• 개요
• 농업
• 생물의학

제11장 세계의 유전자 편집 기술 시장(최종사용자별), 금액(100만 달러), 2022-2032년

• 개요
• 학술기관 및 연구 센터
• 생명과학 기업
• CRO/CMO

제12장 세계의 유전자 편집 기술 시장(지역별), 금액(100만 달러), 2022-2032년

• 개요
• 북미
• 유럽
• 아시아태평양
• 라틴아메리카
• 기타 지역

제13장 기업 개요

• Addgene
• BRAIN Biotech AG
• Cellectis S.A.
• Creative Biolabs
• CRISPR Therapeutics AG
• Danaher Corporation
• DNA Script
• GeneCopoeia, Inc.
• Magento, Inc.
• Merck KGaA
• New England Biolabs, Inc.
• PerkinElmer Inc.
• Precision BioSciences, Inc.
• Sangamo Therapeutics, Inc.
• Takara Bio Inc.
• Thermo Fisher Scientific Inc.

KSA

영문 목차

영문목차

“The global gene editing technologies market is estimated to reach $16.37 billion in 2032, reveals the premium market intelligence study by BIS Research. The study also highlights that the market is set to witness a CAGR of 27.50% during the forecast period 2023-2032.”

The global gene editing technologies market is strongly driven by the continuous introduction of new technologies as well as increased investments and funding from both the government and private sectors. The global gene editing technologies market has witnessed a steady growth in the number of new entrants and continuous utilization of these technologies for the development of therapies for several indications, diagnostic purposes, and drug discovery. This trend is also expected to continue over the forecast period. Therefore, the impact of the aforementioned factors is expected to drive the global gene editing technologies market in the near future.

USP of the Report

• The major USP of the report is the inclusion of a wide range of gene editing products, including kits and enzymes, libraries, antibodies, accessories, and gene editing services that utilize CRISPR, ZFNs, TALENs, and meganucleases for various applications such as agricultural, biomedical, and others.
• The report provides numerical projections for the application in each region and country.
• Apart from this, the report focuses on key trends observed in the global gene editing technologies market.
• The report also comprises key regulations, competitive landscape, key drivers and restraints, patent analysis, business model analysis, and company profiles with a detailed analysis of the strategies undertaken by the major company to strengthen its market presence.

Analyst Perspective

According to Akash Mhaskar, Principal Analyst, BIS Research, "The global gene editing technologies market is flourishing with the advent of time and the introduction of new technologies in the gene editing industry. There is constant ongoing research for the development of novel gene editing technologies. The global gene editing technologies market has witnessed a steady growth in the number of new entrants and investments in gene editing technologies, thereby driving a surge in demand for gene editing products. This trend is also expected to continue over the forecast period. Therefore, the impact of the aforementioned factors is expected to drive the global gene editing technologies market in the near future."

Key Companies Operating in The Market

Key players in the global gene editing technologies market have been analyzed and profiled in the study, including manufacturers involved in new product launches, acquisitions, expansions, and strategic collaborations. Moreover, a detailed competitive benchmarking of the players operating in the global gene editing technologies market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

The key players profiled in the report include Addgene, BRAIN Biotech AG, Cellectis S.A., Creative Biolabs, CRISPR Therapeutics AG, Danaher Corporation, DNA Script, GeneCopoeia, Inc., Magento, Inc., Merck KGaA, New England Biolabs, Inc., PerkinElmer Inc., Precision BioSciences, Inc., Sangamo Therapeutics, Inc., Takara Bio Inc., and Thermo Fisher Scientific Inc.

Key Questions Answered in the Report:

• What are the three potential scenarios in which the global gene editing technologies market growth can unfold during 2022-2032?
• What are the key trends influencing the global gene editing technologies market, and what is their potential for impacting the market?
• What is the patent landscape of the global gene editing technologies market like? Which year and country witnessed the maximum patent filing between January 2018 and December 2022?
• What are the key regulations that impact the growth of the global gene editing technologies market?
• What are the key differences in the various genome editing technologies available in the market?
• What are the key drivers, restraints, and opportunities for the gene editing technologies market? What will be their impact on the market in short-, mid-, and long-term duration?
• Which offering is projected to be the fastest-growing segment during the forecast period 2023-2032?
• Which segmentation holds the largest market share of the gene editing technologies market based on application? Which one of those segments is expected to be the fastest growing segment during the forecast period 2023-2032?
• Who are the major end users of the gene editing technologies market? Which end user held the largest share of the market in 2022?
• What is the competitive landscape in the global gene editing technologies market?
• Who are the key players in the global gene editing technologies market, and what are their product offerings in the market?

Industry Overview

The global gene editing technologies market was valued at $1.81 billion in 2022 and is anticipated to reach $16.37 billion by 2032, witnessing a CAGR of 27.50% during the forecast period 2023-2032. The growth in the global gene editing technologies market is expected to be driven by an increase in the need for personalized medicine. In addition, the introduction of new technologies fuelled the growth of gene editing technologies.

Market Lifecycle Stage

The global gene editing technologies market is in progressing phase. The creation, production, and distribution of tools and services for gene editing are under the purview of the gene editing technology market. Utilizing ways to change DNA sequences, gene editing technologies can be used to treat genetic illnesses, create disease-resistant crops, and generate study models for animals. The market for gene editing technology is made up of numerous businesses that sell CRISPR-Cas9, TALENs, and zinc finger nucleases, among other types of gene editing tools. Researchers, pharmaceutical corporations, and biotech companies employ these techniques to create novel treatments, vaccines, and diagnostic devices.

Moreover, manufacturers began to produce application-specific gene editing technologies in recent years.

Impact

Clustered regularly interspaced short palindromic repeats Cas9 (CRISPR-Cas9) and other gene editing technologies have the potential to revolutionize the healthcare sector and have a big impact on the world economy. Treatments for genetic problems and diseases such as cancer, HIV, and cystic fibrosis may become more accurate and successful because of gene editing technology. This might result in lower healthcare expenses and better patient outcomes. New intellectual property rights could be established because of the advancement of gene editing technologies, which would lead to a sharp rise in the number of patent applications.

Market Segmentation:

Segmentation 1: by Offering

• Gene Editing Products
• Gene Editing Services

Based on offering, the gene editing products segment in the global gene editing technologies market dominated in FY2022.

Segmentation 2: by Technology

• CRISPR Gene Editing Technology
• Non-CRISPR Gene Editing Technology

Based on technology, the global gene editing technologies market was dominated by the CRISPR gene editing technology segment in FY2022.

Segmentation 3: by Application

• Agriculture
• Biomedical

Based on application, the biomedical segment accounted for the largest share of the global gene editing technologies market in FY2022.

Segmentation 4: by End User

• Academic Institutes and Research Centres
• Life Sciences Companies
• Contract Research Organizations (CROs)/ Contract Manufacturing Organizations (CMOs)

Based on end user, the global gene editing technologies market is dominated by the life sciences companies segment in FY2022.

Segmentation 5: by Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Rest-of-the-World

In 2022 the North America gene editing technologies market dominated the global market with a 42.85% market share, and it is expected to hold its dominance throughout the forecast period 2023-2032. However, the Asia-Pacific (APAC) region, constituting several emerging economies, is expected to register the highest CAGR of 29.64% during the forecast period 2023-2032.

Recent Developments in the Global Gene Editing Technologies Market

• In March 2023, Seamless Therapeutics launched with $12.5 million seed financing to advance a transformative gene editing platform based on programmable precision designer recombinases.

• In June 2022, Precision BioSciences, Inc. entered into an exclusive worldwide in vivo gene editing research and development collaboration and license agreement with Novartis AG to develop a custom ARCUS nuclease that would be designed to insert, in vivo, a therapeutic transgene at a "safe harbor" location in the genome as a potential one-time transformative treatment option for diseases including certain hemoglobinopathies such as sickle cell disease and beta-thalassemia.

• In November 2021, Cytovia Therapeutics, Inc. and Cellectis S.A. expanded their TALEN gene-edited iNK partnership to enable broader collaboration in China.

• In February 2022, Integrated DNA Technologies, Inc. (IDT), a provider of global genomics solutions, introduced Alt-R HDR Donor Blocks to support researchers in advancing scientific breakthroughs in gene editing. This enhanced solution was designed to improve homology-directed repair (HDR) rates in large fragment knock-in experiments.

• In March 2023, Intellia Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) approved the Investigational New Drug (IND) Application for NTLA-2002. This was an in vivo investigational therapy based on CRISPR, intended for the treatment of Hereditary Angioedema (HAE).

• In April 2022, Thermo Fisher Scientific Inc.'s latest Gibco CTS TrueCut Cas9 Protein, manufactured under Good Manufacturing Practices (GMP), facilitates genome editing for both research and manufacturing purposes, including research on CAR T-cell therapy.

• In November 2022, Ionis Pharmaceuticals, Inc. and Metagenomi announced a collaboration that may bring together Ionis' extensive knowledge in RNA-targeted therapeutics with Metagenomi's versatile next-generation gene editing systems. The aim of this collaboration was to pursue both established and new genetic targets that may offer the potential for expanding treatment options for patients.

Demand - Drivers and Limitations

The following are the demand drivers for the global gene editing technologies market:

• Introduction of New Technologies Fuelling the Growth of Gene Editing Technologies
• Increasing Investments and Funding Opportunities in Gene Editing Space
• Increased Demand for Personalized Medicines

The market is expected to face some limitations due to the following challenges:

• Limited Expertise and Facilities for Gene Editing Technologies
• Ethical Considerations and Their Consequences Regarding Human Gene Editing

How can this report add value to an organization?

• Workflow/Innovation Strategy: The gene editing technologies market (by offering) has been segmented into gene editing products and gene editing services. Moreover, the study provides the reader with a detailed understanding of the different applications of gene editing technologies in agricultural and biomedical.

• Growth/Marketing Strategy: Gene editing technologies are being used for agricultural, biomedical, and other applications. Various companies are providing gene editing products and services, which is also the key strategy for market players to excel in the current gene editing technologies market.

• Competitive Strategy: Key players in the global gene editing technologies market have been analyzed and profiled in the study, including manufacturers involved in new product launches, acquisitions, expansions, and strategic collaborations. Moreover, a detailed competitive benchmarking of the players operating in the global gene editing technologies market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The success of gene editing technologies has sparked efforts to promote treatments. A stronger focus on the gene editing demand has become essential as the need to cater to the clinical and commercial production of cells, together with the growing amount of substantial clinical data resulting from these technologies, arises. The increased demand for treatments is fuelling the expansion of gene editing technology manufacturers and providing them with numerous opportunities to spread out across different regions and improve their market presence.

Key Companies Profiled:

Table of Contents

1 Product Definition

• 1.1 Inclusion and Exclusion Criteria

2 Market Scope

• 2.1 Scope of Work
• 2.2 Key Questions Answered in the Report

3 Research Methodology

4 Market Overview

• 4.1 Market Overview
• 4.2 Market Footprint and Potential Growth Scenario
  • 4.2.1 Realistic Growth Scenario
  • 4.2.2 Optimistic Growth Scenario
  • 4.2.3 Pessimistic Growth Scenario
• 4.3 Evolution of Gene Editing Technologies
• 4.4 Clinical Trials

5 Industry Outlook

• 5.1 Regulatory Landscape
  • 5.1.1 Legal Requirements and Frameworks in the U.S.
    • 5.1.1.1 Clinical Trial Authorization
    • 5.1.1.2 Marketing Authorization
    • 5.1.1.3 USFDA Guidelines for BLA Submission
    • 5.1.1.4 Post-Authorization Regulations
  • 5.1.2 Legal Requirements and Frameworks in Europe
    • 5.1.2.1 EMA Biologics License Application Process
    • 5.1.2.2 Centralized Procedure
    • 5.1.2.3 Decentralized Procedure
    • 5.1.2.4 Mutual-Recognition Procedure
    • 5.1.2.5 National Procedure
  • 5.1.3 Legal Requirements and Frameworks in Asia-Pacific
    • 5.1.3.1 Legal Requirements and Framework in Japan
  • 5.1.4 Expedited Regulatory Designations Around the World
• 5.2 Product Benchmarking
  • 5.2.1 Product Benchmarking (by Technology)
  • 5.2.2 Comparative Analysis
• 5.3 Technology Adoption Matrix
• 5.4 Industry Trends
  • 5.4.1 Leveraging Collaboration as a Major Key Strategies to Create Opportunities for Gene Editing Technologies
  • 5.4.2 Growing Focus on Gene Therapies
• 5.5 Patent Analysis
  • 5.5.1 Patent Analysis (by Year)
  • 5.5.2 Patent Analysis (by Technology)
  • 5.5.3 Patent Analysis (by Region)
  • 5.5.4 Patent Analysis (by Country)

6 Global Gene Editing Technologies Market: Market Dynamics

• 6.1 Business Drivers
  • 6.1.1 Introduction of New Technologies Fuelling the Growth of Gene Editing Technologies
  • 6.1.2 Increasing Investments and Funding Opportunities in Gene Editing Space
  • 6.1.3 Increased Demand for Personalized Medicines
  • 6.1.4 Impact Analysis
• 6.2 Business Restraints
  • 6.2.1 Limited Expertise and Facilities for Gene Editing Technologies
  • 6.2.2 Ethical Considerations and Their Consequences Regarding Human Gene Editing
  • 6.2.3 Impact Analysis
• 6.3 Business Opportunities
  • 6.3.1 Increasing Numbers of Clinical Trials Utilizing Gene Editing Technologies for the Treatment of Genetic Diseases
  • 6.3.2 Growing Applications of Gene Editing Technologies in Agri-Food Tech

7 Global Gene Editing Technologies Market: Competitive Insights

• 7.1 Key Developments and Strategies
  • 7.1.1 Funding Activities
  • 7.1.2 New Offerings
  • 7.1.3 Mergers and Acquisitions
  • 7.1.4 Partnerships, Alliances, and Business Expansions
  • 7.1.5 Regulatory and Legal Activities
• 7.2 Key Development Analysis
• 7.3 Company Share Analysis

8 Global Gene Editing Technologies Market (by Offering), Value ($Million), 2022-2032

• 8.1 Overview
• 8.2 Gene Editing Products
  • 8.2.1 Kits and Enzymes
    • 8.2.1.1 CRISPR
      • 8.2.1.1.1 Vector-Based Cas9
      • 8.2.1.1.2 DNA-Free Cas9
    • 8.2.1.2 Non-CRISPR
  • 8.2.2 Antibodies
  • 8.2.3 Libraries
  • 8.2.4 Accessories
• 8.3 Gene Editing Services

9 Global Gene Editing Technologies Market (by Technology), Value ($Million), 2022-2032

• 9.1 Overview
• 9.2 CRISPR Gene Editing Technology
• 9.3 Non-CRISPR Gene Editing Technology
  • 9.3.1 Zinc-Finger Nucleases (ZFNs)
  • 9.3.2 TAL Effector Nucleases (TALENs)
  • 9.3.3 Meganucleases

10 Global Gene Editing Technologies Market (by Application), Value ($Million), 2022-2032

• 10.1 Overview
• 10.2 Agricultural
• 10.3 Biomedical
  • 10.3.1 Drug Discovery
  • 10.3.2 Gene Therapy
  • 10.3.3 Diagnostics

11 Global Gene Editing Technologies Market (by End User), Value ($Million), 2022-2032

• 11.1 Overview
• 11.2 Academic Institutes and Research Centers
• 11.3 Life Sciences Companies
• 11.4 Contract Research Organizations (CROs)/ Contract Manufacturing Organizations (CMOs)

12 Global Gene Editing Technologies Market (by Region), Value ($Million), 2022-2032

• 12.1 Overview
• 12.2 North America
  • 12.2.1 North America Gene Editing Technologies Market (by Application)
  • 12.2.2 North America Gene Editing Technologies Market (by Technology)
  • 12.2.3 North America Gene Editing Technologies Market (by Country)
    • 12.2.3.1 U.S.
      • 12.2.3.1.1 U.S. Gene Editing Technologies Market (by Application)
      • 12.2.3.1.2 U.S. Gene Editing Technologies Market (by Technology)
    • 12.2.3.2 Canada
      • 12.2.3.2.1 Canada Gene Editing Technologies Market (by Application)
      • 12.2.3.2.2 Canada Gene Editing Technologies Market (by Technology)
• 12.3 Europe
  • 12.3.1 Europe Gene Editing Technologies Market (by Application)
  • 12.3.2 Europe Gene Editing Technologies Market (by Technology)
  • 12.3.3 Europe Gene Editing Technologies Market (by Country)
    • 12.3.3.1 Germany
      • 12.3.3.1.1 Germany Gene Editing Technologies Market (by Application)
      • 12.3.3.1.2 Germany Gene Editing Technologies Market (by Technology)
    • 12.3.3.2 U.K.
      • 12.3.3.2.1 U.K. Gene Editing Technologies Market (by Application)
      • 12.3.3.2.2 U.K. Gene Editing Technologies Market (by Technology)
    • 12.3.3.3 Switzerland
      • 12.3.3.3.1 Switzerland Gene Editing Technologies Market (by Application)
      • 12.3.3.3.2 Switzerland Gene Editing Technologies Market (by Technology)
    • 12.3.3.4 France
      • 12.3.3.4.1 France Gene Editing Technologies Market (by Application)
      • 12.3.3.4.2 France Gene Editing Technologies Market (by Technology)
    • 12.3.3.5 Spain
      • 12.3.3.5.1 Spain Gene Editing Technologies Market (by Application)
      • 12.3.3.5.2 Spain Gene Editing Technologies Market (by Technology)
    • 12.3.3.6 Italy
      • 12.3.3.6.1 Italy Gene Editing Technologies Market (by Application)
      • 12.3.3.6.2 Italy Gene Editing Technologies Market (by Technology)
    • 12.3.3.7 Rest-of-Europe
      • 12.3.3.7.1 Rest-of-Europe Gene Editing Technologies Market (by Application)
      • 12.3.3.7.2 Rest-of-Europe Gene Editing Technologies Market (by Technology)
• 12.4 Asia-Pacific
  • 12.4.1 Asia-Pacific Gene Editing Technologies Market (by Application)
  • 12.4.2 Asia-Pacific Gene Editing Technologies Market (by Technology)
  • 12.4.3 Asia-Pacific Gene Editing Technologies Market (by Country)
    • 12.4.3.1 China
      • 12.4.3.1.1 China Gene Editing Technologies Market (by Application)
      • 12.4.3.1.2 China Gene Editing Technologies Market (by Technology)
    • 12.4.3.2 Japan
      • 12.4.3.2.1 Japan Gene Editing Technologies Market (by Application)
      • 12.4.3.2.2 Japan Gene Editing Technologies Market (by Technology)
    • 12.4.3.3 India
      • 12.4.3.3.1 India Gene Editing Technologies Market (by Application)
      • 12.4.3.3.2 India Gene Editing Technologies Market (by Technology)
    • 12.4.3.4 Australia
      • 12.4.3.4.1 Australia Gene Editing Technologies Market (by Application)
      • 12.4.3.4.2 Australia Gene Editing Technologies Market (by Technology)
    • 12.4.3.5 Singapore
      • 12.4.3.5.1 Singapore Gene Editing Technologies Market (by Application)
      • 12.4.3.5.2 Singapore Gene Editing Technologies Market (by Technology)
    • 12.4.3.6 South Korea
      • 12.4.3.6.1 South Korea Gene Editing Technologies Market (by Application)
      • 12.4.3.6.2 South Korea Gene Editing Technologies Market (by Technology)
    • 12.4.3.7 Rest-of-Asia-Pacific
      • 12.4.3.7.1 Rest-of-Asia-Pacific Gene Editing Technologies Market (by Application)
      • 12.4.3.7.2 Rest-of-Asia-Pacific Gene Editing Technologies Market (by Technology)
• 12.5 Latin America
  • 12.5.1 Latin America Gene Editing Technologies Market (by Application)
  • 12.5.2 Latin America Gene Editing Technologies Market (by Technology)
  • 12.5.3 Latin America Gene Editing Technologies Market (by Country)
    • 12.5.3.1 Brazil
      • 12.5.3.1.1 Brazil Gene Editing Technologies Market (by Application)
      • 12.5.3.1.2 Brazil Gene Editing Technologies Market (by Technology)
    • 12.5.3.2 Mexico
      • 12.5.3.2.1 Mexico Gene Editing Technologies Market (by Application)
      • 12.5.3.2.2 Mexico Gene Editing Technologies Market (by Technology)
    • 12.5.3.3 Rest-of-Latin America
      • 12.5.3.3.1 Rest-of-Latin America Gene Editing Technologies Market (by Application)
      • 12.5.3.3.2 Rest-of-Latin America Gene Editing Technologies Market (by Technology)
• 12.6 Rest-of-the-World
  • 12.6.1 Rest-of-the-World Gene Editing Technologies Market (by Application)
  • 12.6.2 Rest-of-the-World Gene Editing Technologies Market (by Technology)

13 Company Profiles

• 13.1 Addgene
  • 13.1.1 Company Overview
  • 13.1.2 Role of Addgene in the Global Gene Editing Technologies Market
  • 13.1.3 Major Products: Key Specifications
  • 13.1.4 Key Competitors
  • 13.1.5 Analyst Perspective
• 13.2 BRAIN Biotech AG
  • 13.2.1 Company Overview
  • 13.2.2 Role of BRAIN Biotech AG in the Global Gene Editing Technologies Market
  • 13.2.3 Major Product: Key Specifications
  • 13.2.4 Key Competitors
  • 13.2.5 Financials
  • 13.2.6 Key Insights about the Financial Health of the Company
  • 13.2.7 Analyst Perspective
• 13.3 Cellectis S.A.
  • 13.3.1 Company Overview
  • 13.3.2 Role of Cellectis S.A. in the Global Gene Editing Technologies Market
  • 13.3.3 Major Product: Key Specifications
  • 13.3.4 Key Competitors
  • 13.3.5 Financials
  • 13.3.6 Key Insights about the Financial Health of the Company
  • 13.3.7 Analyst Perspective
• 13.4 Creative Biolabs
  • 13.4.1 Company Overview
  • 13.4.2 Role of Creative Biolabs in the Global Gene Editing Technologies Market
  • 13.4.3 Major Products: Key Specifications
  • 13.4.4 Key Competitors
  • 13.4.5 Analyst Perspective
• 13.5 CRISPR Therapeutics AG
  • 13.5.1 Company Overview
  • 13.5.2 Role of CRISPR Therapeutics AG in the Global Gene Editing Technologies Market
  • 13.5.3 Major Product: Key Specifications
  • 13.5.4 Key Competitors
  • 13.5.5 Financials
  • 13.5.6 Key Insights about the Financial Health of the Company
  • 13.5.7 Analyst Perspective
• 13.6 Danaher Corporation
  • 13.6.1 Company Overview
  • 13.6.2 Role of Danaher Corporation in the Global Gene Editing Technologies Market
  • 13.6.3 Major Products: Key Specifications
  • 13.6.4 Key Competitors
  • 13.6.5 Financials
  • 13.6.6 Key Insights about the Financial Health of the Company
  • 13.6.7 Analyst Perspective
• 13.7 DNA Script
  • 13.7.1 Company Overview
  • 13.7.2 Role of DNA Script in the Global Gene Editing Technologies Market
  • 13.7.3 Major Products: Key Specifications
  • 13.7.4 Key Competitors
  • 13.7.5 Analyst Perspective
• 13.8 GeneCopoeia, Inc.
  • 13.8.1 Company Overview
  • 13.8.2 Role of GeneCopoeia, Inc. in the Global Gene Editing Technologies Market
  • 13.8.3 Major Product: Key Specifications
  • 13.8.4 Key Competitors
  • 13.8.5 Analyst Perspective
• 13.9 Magento, Inc.
  • 13.9.1 Company Overview
  • 13.9.2 Role of Magento, Inc. in the Global Gene Editing Technologies Market
  • 13.9.3 Major Products: Key Specifications
  • 13.9.4 Key Competitors
  • 13.9.5 Analyst Perspective
• 13.1 Merck KGaA
  • 13.10.1 Company Overview
  • 13.10.2 Role of Merck KGaA in the Global Gene Editing Technologies Market
  • 13.10.3 Major Products: Key Specifications
  • 13.10.4 Key Competitors
  • 13.10.5 Financials
  • 13.10.6 Key Insights about the Financial Health of the Company
  • 13.10.7 Analyst Perspective
• 13.11 New England Biolabs, Inc.
  • 13.11.1 Company Overview
  • 13.11.2 Role of New England Biolabs, Inc. in the Global Gene Editing Technologies Market
  • 13.11.3 Major Products: Key Specifications
  • 13.11.4 Key Competitors
  • 13.11.5 Analyst Perspective
• 13.12 PerkinElmer Inc.
  • 13.12.1 Company Overview
  • 13.12.2 Role of PerkinElmer Inc. in the Global Gene Editing Technologies Market
  • 13.12.3 Major Product: Key Specifications
  • 13.12.4 Key Competitors
  • 13.12.5 Financials
  • 13.12.6 Key Insights about the Financial Health of the Company
  • 13.12.7 Analyst Perspective
• 13.13 Precision BioSciences, Inc.
  • 13.13.1 Company Overview
  • 13.13.2 Role of Precision BioSciences, Inc. in the Global Gene Editing Technologies Market
  • 13.13.3 Major Product: Key Specifications
  • 13.13.4 Key Competitors
  • 13.13.5 Financials
  • 13.13.6 Key Insights about the Financial Health of the Company
  • 13.13.7 Analyst Perspective
• 13.14 Sangamo Therapeutics, Inc.
  • 13.14.1 Company Overview
  • 13.14.2 Role of Sangamo Therapeutics, Inc. in the Global Gene Editing Technologies Market
  • 13.14.3 Major Product: Key Specifications
  • 13.14.4 Key Competitors
  • 13.14.5 Financials
  • 13.14.6 Key Insights about the Financial Health of the Company
  • 13.14.7 Analyst Perspective
• 13.15 Takara Bio Inc.
  • 13.15.1 Company Overview
  • 13.15.2 Role of Takara Bio Inc. in the Global Gene Editing Technologies Market
  • 13.15.3 Major Products: Key Specifications
  • 13.15.4 Key Competitors
  • 13.15.5 Financials
  • 13.15.6 Key Insights about the Financial Health of the Company
  • 13.15.7 Analyst Perspective
• 13.16 Thermo Fisher Scientific Inc.
  • 13.16.1 Company Overview
  • 13.16.2 Role of Thermo Fisher Scientific Inc. in the Global Gene Editing Technologies Market
  • 13.16.3 Major Products: Key Specifications
  • 13.16.4 Key Competitors
  • 13.16.5 Financials
  • 13.16.6 Key Insights about the Financial Health of the Company
  • 13.16.7 Analyst Perspective

관련자료